KH 901Alternative Names: KH901
Latest Information Update: 20 Aug 2015
At a glance
- Originator Chengdu Kanghong Biological Science & Technology
- Class Cancer vaccines; Oncolytic viruses
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Aug 2015 No recent reports on development identified - Phase-II for Cancer in China (Parenteral)
- 08 Apr 2011 Phase-II clinical trials in Cancer in China (Parenteral)